This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Hoffmann-La Roche Inc., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Active years: 2016.
Company Filing History:
1 out of 5,016 
1 out of 910 
Years Active: 2016
Title: Ralph J Garippa: Innovator in Cytotoxic Inhibitors
Introduction
Ralph J Garippa is a notable inventor based in Roseland, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of selective inhibitors for undifferentiated cells. His work has implications for various medical applications, especially in cancer research.
Latest Patents
Garippa holds 1 patent for his invention titled "Selective inhibitors of undifferentiated cells." This patent discloses the uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells. It also includes pharmaceutical compositions comprising these compounds and methods for identifying lead candidates for inhibiting undifferentiated cells. Furthermore, the patent discusses the use of an SCD-1 inhibitor as a cytotoxic agent against undifferentiated cells.
Career Highlights
Throughout his career, Garippa has worked with prominent organizations, including Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and Hoffmann-La Roche Inc. His experience in these companies has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of Garippa's notable coworkers include Uri Ben-David and Nissim Benvenisty. Their collaborative efforts have further advanced the research and development of innovative solutions in biotechnology.
Conclusion
Ralph J Garippa's contributions to the field of cytotoxic inhibitors highlight his role as an influential inventor. His patent work and collaborations reflect his commitment to advancing medical science and improving therapeutic options.